Access cutting-edge systemic sclerosis treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.
Access systemic sclerosis specialists in Ann Arbor at no cost
This study follows strict safety protocols and ethical guidelines
All study-related systemic sclerosis treatment provided free
The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment period of up to 48 weeks and a safety follow-up period. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod PH20 SC or placebo. The total study duration can be up to approximately 15 months.
Sponsor: argenx
Check if you qualify for this systemic sclerosis clinical trial in Ann Arbor, MI
If you're searching for systemic sclerosis treatment options in Ann Arbor, MI, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced systemic sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.